Searched for
PHARMA SECTOR
Sensex rises over 200 points, Nifty above 24,000; Maruti Suzuki shares jump 3%Indian stock markets rebounded on Tuesday, with both Sensex and Nifty climbing approximately 0.4% after a dip in the previous session. The ...- Indian envoy holds talks with senior Chinese commerce ministry official on trade tiesIndian Ambassador Vikram Doraiswami met a senior Chinese Commerce Ministry official to boost trade and commercial cooperation. The discussi...
- Market wrap: Sensex falls 372 points, Nifty closes below 23,950; Kotak Mahindra Bank drops 3%Indian markets ended lower as Sensex and Nifty snapped a two-session winning streak, pressured by geopolitical tensions in the Middle East ...
- 2 top stock recommendations from Vinay RajaniIndian equity markets are experiencing a cautious phase, consolidating within a defined range as fresh buying momentum remains elusive. Tec...
- Capacity augmentation, value-added applications critical for making India leader in stainless steel productionWith a growing domestic market and potential in sectors like green hydrogen and pharmaceuticals, India aims to be a manufacturing and innov...
- Nifty has more room to run; stay selective: AnalystsIndian stock markets are showing cautious optimism, with the Nifty eyeing the 24,300-25,000 zone amid ongoing volatility. Analysts recommen...
- Dalal Street Week Ahead: Nifty to test crucial 24,500 level; breakout may define next trendIndian markets navigated a subdued week, ending with modest gains as Nifty hovered near a crucial resistance zone between 24,160 and 24,500...
- Trade disruptions, API dependence, compliance costs: Pharma MSMEs spell out policy priorities on World MSME DayIndian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry represent...
- Pharma, power & mid-sized banks: Where Mayuresh Joshi is putting money to work right nowIndian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...
- Oil slide powers India's stock benchmarks to longest weekly winning run 7 monthsIndian stock markets achieved their longest winning streak in seven months, with the Nifty 50 and BSE Sensex closing higher. Falling crude ...
- India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesIndian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...
- Nominal GDP growth could fuel largecap recovery; pharma, auto ancillaries remain preferred bets: Shreyash DevalkarIndian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...
- India's growth story, not AI trade reversal, will drive foreign flows: Sameer DalalIndia's economic strength, not AI's decline, will drive foreign capital inflows, according to Sameer Dalal. He believes AI's market correct...
- Honasa Consumer to buy 58% stake in Fluence Pharma at Rs 135-crore enterprise valueMamaearth's parent company, Honasa Consumer, is acquiring a majority stake in nutraceuticals brand Fluence Pharma for ₹135 crore. This stra...
- NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chainNiti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think ta...
- Ahead of Market: 10 things that will decide stock market action on WednesdaySensex and Nifty plunged over 1% on Tuesday amid global market weakness, IT sector losses, a weaker rupee and fresh foreign fund outflows. ...
- Honasa Consumer to acquire majority stake in Fluence Pharma at Rs 135-crore valuationHonasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's ...
- Defence valuations 'obnoxious'; private banks look strong: Sandip Sabharwal's full market playbookInvestor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- India's defence export boom could hit ₹65,000 crore by 2030; pvt sector startups the real play: Sunil SubramaniamIndia's defence exports are poised to surpass government targets, reaching ₹60,000-65,000 crore by 2030, according to market expert Sunil S...
Load More
